BRPI0811617A2 - derivados de primidina e composições como inibidores de c-kit e pdgfr quinase. - Google Patents

derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.

Info

Publication number: BRPI0811617A2
Authority: BR; Brazil
Prior art keywords: kit; derivatives; compositions; primidine; kinase inhibitors
Prior art date: 2007-05-04

Application number

BRPI0811617A

Other languages

English (en)

Inventor

Molteni Valentina

Lu Xiaodong

Li Xiaolin

Original Assignee

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-04

Filing date

2008-05-01

Publication date

2017-06-06

2008-05-01 Application filed by Irm Llc filed Critical Irm Llc

2017-06-06 Publication of BRPI0811617A2 publication Critical patent/BRPI0811617A2/pt

Links

102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title abstract 2
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title abstract 2
101150093908 PDGFRB gene Proteins 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
108091000080 Phosphotransferase Proteins 0.000 abstract 2
230000002159 abnormal effect Effects 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
102000020233 phosphotransferase Human genes 0.000 abstract 2
102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 abstract 1
108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000002074 deregulated effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003230 pyrimidines Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Addiction (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Oncology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)

BRPI0811617A 2007-05-04 2008-05-01 derivados de primidina e composições como inibidores de c-kit e pdgfr quinase. BRPI0811617A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US91603507P	2007-05-04	2007-05-04
PCT/US2008/062304 WO2008137605A1 (en)	2007-05-04	2008-05-01	Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0811617A2 true BRPI0811617A2 (pt)	2017-06-06

Family

ID=39616606

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0811617A BRPI0811617A2 (pt)	2007-05-04	2008-05-01	derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.

Country Status (13)

Country	Link
US (1)	US8268850B2 (pt)
EP (1)	EP2148874B1 (pt)
JP (1)	JP5160636B2 (pt)
KR (1)	KR101122481B1 (pt)
CN (1)	CN101687853A (pt)
AT (1)	ATE544761T1 (pt)
AU (1)	AU2008247668B2 (pt)
BR (1)	BRPI0811617A2 (pt)
CA (1)	CA2686378C (pt)
EA (1)	EA017269B1 (pt)
ES (1)	ES2381318T3 (pt)
MX (1)	MX2009011950A (pt)
WO (1)	WO2008137605A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2697077C (en)	2007-08-22	2012-10-16	Irm Llc	2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
CA2697081C (en)	2007-08-22	2013-04-23	Irm Llc	5-(4-(haloalkoxy)phenyl)pyrimidine-2-amine compounds and compositions as kinase inhibitors
CA2714700C (en)	2008-02-22	2013-07-30	Irm Llc	Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
TWI490214B (zh)	2008-05-30	2015-07-01	艾德克上野股份有限公司	苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
US8735417B2 (en)	2009-12-17	2014-05-27	Merck Sharp & Dohme Corp.	Aminopyrimidines as Syk inhibitors
WO2011075517A1 (en)	2009-12-17	2011-06-23	Merck Sharp & Dohme Corp.	Aminopyrimidines as syk inhibitors
EP2694486B1 (en)	2011-04-01	2018-01-10	University of Utah Research Foundation	Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
BR112013025387B1 (pt)	2011-04-01	2021-07-27	University Of Utah Research Foundation	Compostos análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl, uso dos ditos compostos para o tratamento de um distúrbio de proliferação celular descontrolada, bem como kit compreendendo ditos compostos
US9145391B2 (en)	2011-05-10	2015-09-29	Merck Sharp & Dohme Corp.	Bipyridylaminopyridines as Syk inhibitors
EP2707357B1 (en)	2011-05-10	2017-01-18	Merck Sharp & Dohme Corp.	Pyridyl aminopyridines as syk inhibitors
MX2013013090A (es)	2011-05-10	2013-12-16	Merck Sharp & Dohme	Aminopirimidinas como inhibidores de tirosina cinaza del bazo.
US9296703B2 (en)	2012-10-04	2016-03-29	University Of Utah Research Foundation	Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
WO2014055928A2 (en)	2012-10-04	2014-04-10	University Of Utah Research Foundation	Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
EP3007689B1 (en)	2013-01-10	2018-03-07	Pulmokine, Inc.	Non-selective kinase inhibitors
MX394360B (es)	2013-03-14	2025-03-24	Sumitomo Pharma Oncology Inc	Inhibidores de jak2 y alk2 y metodos para su uso.
CN104458674A (zh) *	2013-09-12	2015-03-25	中国药科大学	一种筛选血管内皮生长因子1激酶抑制剂高通量筛选方法
US9925184B2 (en)	2013-10-11	2018-03-27	Pulmokine, Inc.	Spray-dry formulations
RU2763525C2 (ru)	2016-10-27	2021-12-30	Пульмокин, Инк.	Комбинированная терапия для лечения легочной гипертензии
US20210106581A1 (en) *	2018-02-21	2021-04-15	Melior Pharmaceuticals I, Inc.	Treatment Of Liver Diseases
CN112533602A (zh)	2018-04-05	2021-03-19	大日本住友制药肿瘤公司	Axl激酶抑制剂及其用途
MX2021000977A (es)	2018-07-26	2021-04-12	Sumitomo Pharma Oncology Inc	Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
TWI759829B (zh) *	2019-08-23	2022-04-01	財團法人生物技術開發中心	作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
CN112745300A (zh) *	2021-01-21	2021-05-04	杭州浙中医药科技有限公司	一种制备n-(5-羧基-2-甲基苯基)-4-(3-吡啶)-2-嘧啶胺的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0164204A1 (en)	1984-05-12	1985-12-11	FISONS plc	Novel pharmaceutically useful pyrimidines
GB9914258D0 (en) *	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
GB0022438D0 (en) *	2000-09-13	2000-11-01	Novartis Ag	Organic Compounds
US7122544B2 (en)	2000-12-06	2006-10-17	Signal Pharmaceuticals, Llc	Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en)	2000-12-06	2006-10-31	Signal Pharmaceuticals, Llc	Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7429599B2 (en)	2000-12-06	2008-09-30	Signal Pharmaceuticals, Llc	Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
AU2002342878A1 (en)	2001-05-16	2002-11-25	Axxima Pharmaceuticals Ag	Pyridylpyrimidine derivatives as effective compounds against prion diseases
GB0215676D0 (en) *	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0222514D0 (en) *	2002-09-27	2002-11-06	Novartis Ag	Organic compounds
UA94570C2 (en)	2004-09-09	2011-05-25	Натко Фарма Лимитед	Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
MX2007004488A (es)	2004-10-13	2007-09-11	Wyeth Corp	Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
US20060247250A1 (en)	2005-03-16	2006-11-02	Targegen, Inc.	Pyrimidine inhibitors of kinases
KR100674813B1 (ko) *	2005-08-05	2007-01-29	일양약품주식회사	Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
EP1928236B1 (en)	2005-09-27	2011-11-23	Irm Llc	Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
EP2152688A1 (en)	2007-05-04	2010-02-17	Irm Llc	Compounds and compositions as c-kit and pdgfr kinase inhibitors
EA016329B1 (ru) *	2007-05-04	2012-04-30	Айрм Ллк	СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR

2008
- 2008-05-01 EP EP08747412A patent/EP2148874B1/en not_active Not-in-force
- 2008-05-01 EA EA200901483A patent/EA017269B1/ru not_active IP Right Cessation
- 2008-05-01 US US12/598,919 patent/US8268850B2/en not_active Expired - Fee Related
- 2008-05-01 KR KR1020097025278A patent/KR101122481B1/ko not_active Expired - Fee Related
- 2008-05-01 AU AU2008247668A patent/AU2008247668B2/en not_active Ceased
- 2008-05-01 AT AT08747412T patent/ATE544761T1/de active
- 2008-05-01 BR BRPI0811617A patent/BRPI0811617A2/pt not_active IP Right Cessation
- 2008-05-01 ES ES08747412T patent/ES2381318T3/es active Active
- 2008-05-01 WO PCT/US2008/062304 patent/WO2008137605A1/en not_active Ceased
- 2008-05-01 JP JP2010507541A patent/JP5160636B2/ja not_active Expired - Fee Related
- 2008-05-01 CN CN200880023078A patent/CN101687853A/zh active Pending
- 2008-05-01 MX MX2009011950A patent/MX2009011950A/es active IP Right Grant
- 2008-05-01 CA CA2686378A patent/CA2686378C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2008247668A1 (en)	2008-11-13
JP2010526148A (ja)	2010-07-29
EA017269B1 (ru)	2012-11-30
KR101122481B1 (ko)	2012-02-29
US20100190811A1 (en)	2010-07-29
CA2686378A1 (en)	2008-11-13
ATE544761T1 (de)	2012-02-15
CA2686378C (en)	2012-07-24
WO2008137605A1 (en)	2008-11-13
EP2148874A1 (en)	2010-02-03
EP2148874B1 (en)	2012-02-08
CN101687853A (zh)	2010-03-31
US8268850B2 (en)	2012-09-18
JP5160636B2 (ja)	2013-03-13
MX2009011950A (es)	2009-12-11
ES2381318T3 (es)	2012-05-25
EA200901483A1 (ru)	2010-04-30
AU2008247668B2 (en)	2013-01-10
KR20090130342A (ko)	2009-12-22

Legal Events

Date	Code	Title	Description
2017-06-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-09-26	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Publication	Publication Date	Title
BRPI0811617A2 (pt)	2017-06-06	derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.
MX2009011951A (es)	2009-12-11	Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MY167245A (en)	2018-08-14	Compounds and compositions as c-kit kinase inhibitors
MX2010009207A (es)	2011-03-03	Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MX2009011952A (es)	2009-12-11	Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
EA200970447A1 (ru)	2009-10-30	Соединения и композиции в качестве ингибиторов протеинкиназы
TN2014000068A1 (en)	2015-07-01	Compounds and compositions as c-kit kinase inhibitors
MX2014002486A (es)	2014-12-08	Compuestos y composiciones como inhibidores de cinasa pdgfr.
TN2013000348A1 (en)	2015-01-20	Compounds and compositions as trk inhibitors
EA201190158A1 (ru)	2012-04-30	Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
WO2011014795A3 (en)	2011-06-03	Compounds and compositions as syk kinase inhibitors
EA201490537A1 (ru)	2014-07-30	СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit
TW200637547A (en)	2006-11-01	Compounds and compositions as protein kinase inhibitors
CR11430A (es)	2010-07-01	4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpirimidin-2-aminas como inhibidores de cinasas janus
EA201071089A1 (ru)	2011-04-29	Производные хиназолина как модуляторы raf-киназы и способы их применения
TN2012000081A1 (en)	2013-09-19	Compounds and compositions as protein kinase inhibitors
MX2009007944A (es)	2009-08-07	Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
WO2009097287A9 (en)	2009-10-01	Compounds and compositions as kinase inhibitors
UY33597A (es)	2012-04-30	Compuestos y composiciones como inhibidores de la trk
EA201490539A1 (ru)	2014-06-30	Соединения и композиции в качестве ингибиторов c-kit киназы
MX2009006170A (es)	2009-06-19	Compuestos y composiciones como inhibidores de cinasa.
BR112013008523A2 (pt)	2016-07-12	compostos de piridazina carboxamida substituídos
BR112013009260A2 (pt)	2016-07-26	compostos de carboxamida de piridazina substituídos como compostos inibidores de quinase
HK1129898A (en)	2009-12-11	Compounds and compositions as protein kinase inhibitors